AHK-Cu (Copper Tripeptide)

AHK-Cu pairs a plausible mechanism and a clean safety profile with an almost empty human-evidence file. The practical verdict: it is a reasonable, low-risk add-on to a real hair protocol if you go in expecting little, but it is a poor standalone bet and an easy thing to skip in favor of better-supported options. The single AHK-Cu study is in-vitro and ex-vivo from 2007, with no human trial and no replication, per Pyo 2007, so any clinically proven hair growth claim is unsupported for this specific peptide. The two things to keep straight are the naming confusion with GHK-Cu and DAHK, and the off-label injectable use you should avoid.

✅ Best for: People who already run a proven hair protocol, like minoxidil, and want a cheap, low-risk topical to layer on without high expectations. Tinkerers who accept that AHK-Cu rests on a single dish study and are fine experimenting on that basis. Anyone drawn to copper peptides who understands that GHK-Cu is the better-evidenced cousin and is choosing AHK with eyes open. People who value a trivially reversible cosmetic they can stop anytime. Readers who want to understand the naming traps before they shop, since the Copper Tripeptide-1 versus Copper Tripeptide-3 confusion drives a lot of bad marketing, per Wang 2021.

❌ Avoid if: You want an evidence-backed standalone hair-loss treatment, because AHK-Cu has no human trial and minoxidil is the only FDA-approved topical. You would skip the better-studied GHK-Cu to use it, since GHK has the deeper record, per Pickart 2008. You are tempted by gray-market injectable or mesotherapy use, which is off-label, non-approved, and unstudied for AHK-Cu and bypasses the only barrier it was ever tested across. You have a known sensitivity to copper-peptide cosmetics or active scalp irritation. You are relying on product claims rather than the actual evidence, since many serums blend AHK with other actives and you cannot credit any result to AHK-Cu alone, per Liu 2020.